Masaki Fujiwara1, Masatoshi Inagaki2, Naoki Nakaya3, Maiko Fujimori4,5, Yuji Higuchi6, Chinatsu Hayashibara1, Ryuhei So7, Kyoko Kakeda8, Masafumi Kodama7, Yosuke Uchitomi9,10,11, Norihito Yamada1. 1. Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science, Okayama, Japan. 2. Department of Neuropsychiatry, Okayama University Hospital, Okayama, Japan. 3. Department of Preventive Medicine and Epidemiology, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan. 4. Japan Support Center for Suicide Countermeasures, National Institute of Mental Health, National Center for Neurology & Psychiatry, Tokyo, Japan. 5. Division of Health Care Research, QOL Research Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan. 6. Taiyo Hills Hospital, Takahashi, Japan. 7. Okayama Psychiatric Medical Center, Okayama, Japan. 8. Department of Neuropsychiatry, Kochi Medical School, Kochi University, Nankoku, Japan. 9. Innovation Center for Supportive, Palliative and Psychosocial Care, Tokyo, Japan. 10. Department of Psycho-Oncology, National Cancer Center Hospital, Tokyo, Japan. 11. Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Abstract
AIM: The influence of schizophrenic patients' functional disability on cancer screening participation worldwide is unclear. There are few findings on the disparities in schizophrenic patients' participation in cancer screening programs in Asia. The aim of this study was to investigate the screening rate and the associations between screening and symptom severity/functional disability in patients with schizophrenia. METHODS: This cross-sectional study was conducted in a psychiatric hospital outpatient clinic in Japan. We recruited schizophrenic patients meeting the national program criteria for cancer screening for colorectal, gastric, lung, breast, and cervical cancer (n = 224, 223, 224, 110, and 175, respectively). Receipt of cancer screenings was assessed using a self-report questionnaire. Scores on the modified Global Assessment of Functioning (mGAF) were evaluated by participants' primary psychiatrists. RESULTS: Rates of cancer screenings were as follows: 24.1% for colorectal, 21.5% for gastric, 30.8% for lung, 25.5% for breast, and 19.4% for cervical cancer. A multivariable logistic analysis showed that a 1-point increase in severity/disability (100 minus mGAF score) was associated with significantly lower odds ratios (OR) for receipt of cancer screenings, except for breast cancer (OR, 0.95, 95% confidence interval [CI], 0.93-0.98 for colorectal; OR, 0.96, 95%CI, 0.93-0.98 for gastric; OR, 0.95, 95%CI, 0.93-0.97 for lung; OR, 0.97, 95%CI, 0.94-1.00 for breast; and OR, 0.95, 95%CI, 0.92-0.98 for cervical cancer). CONCLUSION: The findings demonstrated low rates of cancer screenings in schizophrenic patients in Japan. Our study suggests the need to encourage attendance at cancer screenings, especially in schizophrenic patients with severe symptoms/functional disability.
AIM: The influence of schizophrenicpatients' functional disability on cancer screening participation worldwide is unclear. There are few findings on the disparities in schizophrenicpatients' participation in cancer screening programs in Asia. The aim of this study was to investigate the screening rate and the associations between screening and symptom severity/functional disability in patients with schizophrenia. METHODS: This cross-sectional study was conducted in a psychiatric hospital outpatient clinic in Japan. We recruited schizophrenicpatients meeting the national program criteria for cancer screening for colorectal, gastric, lung, breast, and cervical cancer (n = 224, 223, 224, 110, and 175, respectively). Receipt of cancer screenings was assessed using a self-report questionnaire. Scores on the modified Global Assessment of Functioning (mGAF) were evaluated by participants' primary psychiatrists. RESULTS: Rates of cancer screenings were as follows: 24.1% for colorectal, 21.5% for gastric, 30.8% for lung, 25.5% for breast, and 19.4% for cervical cancer. A multivariable logistic analysis showed that a 1-point increase in severity/disability (100 minus mGAF score) was associated with significantly lower odds ratios (OR) for receipt of cancer screenings, except for breast cancer (OR, 0.95, 95% confidence interval [CI], 0.93-0.98 for colorectal; OR, 0.96, 95%CI, 0.93-0.98 for gastric; OR, 0.95, 95%CI, 0.93-0.97 for lung; OR, 0.97, 95%CI, 0.94-1.00 for breast; and OR, 0.95, 95%CI, 0.92-0.98 for cervical cancer). CONCLUSION: The findings demonstrated low rates of cancer screenings in schizophrenicpatients in Japan. Our study suggests the need to encourage attendance at cancer screenings, especially in schizophrenicpatients with severe symptoms/functional disability.
Authors: YoungJee Kim; Dong Wook Shin; Hyoung Woo Kim; Jin Hyung Jung; Kyungdo Han; In Young Cho; So Young Kim; Kui Son Choi; Jong Heon Park; Jong Hyock Park; Ichiro Kawachi Journal: Gastric Cancer Date: 2019-11-01 Impact factor: 7.370
Authors: Federica Vallone; Daniela Lemmo; Maria Luisa Martino; Anna Rosa Donizzetti; Maria Francesca Freda; Francesco Palumbo; Elvira Lorenzo; Angelo D'Argenzio; Daniela Caso Journal: Psychooncology Date: 2022-07-12 Impact factor: 3.955
Authors: Jin Young Choi; Kyoung Eun Yeob; Seung Hwa Hong; So Young Kim; Eun-Hwan Jeong; Dong Wook Shin; Jong Heon Park; Gil-Won Kang; Hak Soon Kim; Jong Hyock Park; Ichiro Kawachi Journal: Cancer Control Date: 2021 Jan-Dec Impact factor: 3.302